title: Autoimmune hepatitis in southern Israel: a 15-year multicenter study.
abstract: OBJECTIVE
  In this study we aimed to assess the incidence, prevalence and clinical outcomes of patients with autoimmune hepatitis (AIH) in southern Israel.
  
  
  METHODS
  Case-finding methods and population-based administrative data were used to evaluate the epidemiology and prognostic factors of AIH from 1995 to 2010.
  
  
  RESULTS
  During the study period, the average annual prevalence and incidence of AIH in southern Israel were 11.0/100000 and 0.67/100000, respectively. We identified 100 AIH cases with a mean age of 47.9 years, including 95 women and five men. Type 1 AIH was found in 77 cases, and liver fibrosis and cirrhosis were found in 73.4% and 22.3% of all patients who underwent liver biopsy. In all, 98 patients were treated with a combination of steroids and azathioprine or steroids alone (prednisone and azathioprine in 71, budesonide and azathioprine in 11, prednisone or budesonide alone in six and ten, respectively). Complete remission was recorded in 56 patients, whereas partial response or failure of treatment was noted in 42 patients. In multivariate analysis the independent predictors of remission were the degree of liver fibrosis (mild vs bridging fibrosis (F3) and cirrhosis [F4]) (P=0.003) and level of albumin (P=0.031). The estimated 1-year and 10-year survival for AIH were 96.5% and 89.7%, respectively.
  
  
  CONCLUSIONS
  The prevalence of AIH in Israel is quite similar to that of other European Caucasian populations, with a relatively long-term good prognosis, despite a low rate of response to immunosuppressive therapy.
authors.affiliation: Department of Gastroenterology and Hepatology, Barzilai Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
authors.forename: Jorge-Shmuel
authors.initials: JS
authors.lastname: Delgado
authors.forename: Alina
authors.initials: A
authors.lastname: Vodonos
authors.forename: Stephen
authors.initials: S
authors.lastname: Malnick
authors.forename: Ofra
authors.initials: O
authors.lastname: Kriger
authors.forename: Renana
authors.initials: R
authors.lastname: Wilkof-Segev
authors.forename: Bertha
authors.initials: B
authors.lastname: Delgado
authors.forename: Victor
authors.initials: V
authors.lastname: Novack
authors.forename: Alexander
authors.initials: A
authors.lastname: Rosenthal
authors.forename: Yoram
authors.initials: Y
authors.lastname: Menachem
authors.forename: Ehud
authors.initials: E
authors.lastname: Melzer
authors.forename: Alexander
authors.initials: A
authors.lastname: Fich
mesh_terms: D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D001706:Biopsy; D019819:Budesonide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D019693:Hepatitis, Autoimmune / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D007557:Israel / Q000453:epidemiology; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D015995:Prevalence; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D019819:Budesonide; D001379:Azathioprine; D011241:Prednisone
keywords: Israel; autoimmune hepatitis; epidemiology; outcome; therapy